The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study
Abstract
Introduction: N8-GP (turoctocog alfa pegol) is a recombinant, glycoPEGylated, extended half-life FVIII replacement product approved for treatment of haemophilia A (HA).
Aim: The pathfinder10 (NCT05082116) multicentre, open-label, nonrandomised, single-arm phase 3b trial investigated N8-GP efficacy, safety, and pharmacokinetics in previously treated Chinese patients.
Methods: Patients (≥12 years) with severe HA, FVIII activity <1%, ≥150 exposure days to FVIII products, and no FVIII inhibitors (≥0.6 BU) or history were enrolled and received 50 IU/kg N8-GP prophylaxis every four days for ≥28 weeks. Bleeding episodes were treated with 20-75 IU/kg N8-GP. The primary endpoint was the number of treatment-requiring bleeding episodes (spontaneous, traumatic). Secondary endpoints included haemostatic effect, inhibitor rate, FVIII trough activity, and pharmacokinetics.
Results: Thirty-six patients completed the trial. During 12 months pretrial, 17 (47%) patients received a mixture of episodic and prophylactic regimens, and 1 (3%) episodic treatment only, and the mean (SD) and median number of bleeding episodes during prophylaxis were 11.0 (11.1) and 5.0. During N8-GP prophylaxis, mean (95% CI) and median ABR were 2.55 (1.24; 5.23) and 0.00. No bleeds were reported in 25/36 patients (69.4%). The haemostatic success rate for bleed treatment was 94.8% (73.2; 99.2). Most bleeds (49/52; 94.2%) were treated with ≤2 injections; 42/52 (80.8%) needed 1 injection. Mean FVIII activity trough…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 36 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.